Previous studies have suggested additional beneficial effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors including the lipid-lowering effect; however, results on lipid profile are controversial. Thus, this meta-analysis aimed to determine the effect of SGLT2 inhibitors treatment on lipid levels in patients with type 2 diabetes.

Randomized controlled trials assessing the impact of SGLT2 inhibitors on lipid parameters were searched in PubMed-MEDLINE, SCOPUS, Web of Science, and Google Scholar databases. Meta-analysis was conducted using a random-effects model and generic inverse variance method.

Meta-analysis of 48 randomized controlled trials revealed that SGLT2 inhibitors therapy had a significant increase on total cholesterol (WMD: 0.09 mmol/L, 95 % CI: 0.05, 0.13, I² = 79 %, p < 0.0001), LDL-cholesterol (WMD: 0.10 mmol/L, 95 % CI: 0.07, 0.12, I² = 94 %, p < 0.00001), HDL-cholesterol (WMD: 0.06 mmol/L, 95 % CI: 0.05, 0.08, I² = 99 %, p < 0.00001), and non-HDL-cholesterol (WMD: 0.09 mmol/L, 95 % CI: 0.06, 0.12, I² = 96 %, p < 0.00001). Additionally, SGLT2 inhibitors administration showed a significant decrease in triglyceride levels (WMD: -0.10 mmol/L, 95 % CI: -0.13, -0.07, I² = 96 %, p < 0.00001). Finally, no significant alteration was found on LDL/HDL ratio after SGLT2 inhibitors treatment (WMD: -0.01 mmol/L, 95 % CI: -0.05, 0.03, I² = 99 %, p = 0.65).

In conclusion, SGLT2 inhibitors significantly increase total cholesterol, LDL-cholesterol, non-HDL-cholesterol, and HDL-cholesterol, and decrease triglyceride levels.

先前的研究表明，钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂的其他有益作用包括降脂作用；然而，关于脂质分布的结果是有争议的。因此，这项荟萃分析旨在确定 SGLT2 抑制剂治疗对 2 型糖尿病患者血脂水平的影响。

在 PubMed-MEDLINE、SCOPUS、Web of Science 和 Google Scholar 数据库中搜索了评估 SGLT2 抑制剂对脂质参数影响的随机对照试验。使用随机效应模型和通用逆方差方法进行荟萃分析。

对 48 项随机对照试验的荟萃分析显示，SGLT2 抑制剂治疗显着增加了总胆固醇（WMD：0.09 mmol/L，95 % CI：0.05, 0.13，I ² = 79 %，p < 0.0001）、LDL-胆固醇（WMD：0.10毫摩尔/ L，95％CI：0.07，0.12，我² = 94％，p <0.00001），高密度脂蛋白胆固醇（WMD：0.06毫摩尔/ L，95％CI：0.05，0.08，我² = 99 %，p < 0.00001）和非 HDL-胆固醇（WMD：0.09 mmol/L，95 % CI：0.06, 0.12，I ² = 96 %，p< 0.00001)。此外，SGLT2 抑制剂给药显示甘油三酯水平显着降低（WMD：-0.10 mmol/L，95 % CI：-0.13，-0.07，I ² = 96 %，p < 0.00001）。最后，在 SGLT2 抑制剂治疗后未发现 LDL/HDL 比率有显着变化（WMD：-0.01 mmol/L，95 % CI：-0.05, 0.03，I ² = 99 %，p = 0.65）。

总之，SGLT2抑制剂显着增加总胆固醇、低密度脂蛋白胆固醇、非高密度脂蛋白胆固醇和高密度脂蛋白胆固醇，并降低甘油三酯水平。